CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 83 filers reported holding CYTOSORBENTS CORP in Q1 2020. The put-call ratio across all filers is 1.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $15,304 | -48.2% | 4,263 | -51.4% | 0.00% | – |
| Q1 2023 | $29,531 | +105367.9% | 8,763 | +48583.3% | 0.00% | – |
| Q4 2022 | $28 | -98.6% | 18 | -98.9% | 0.00% | – |
| Q3 2022 | $2,000 | -50.0% | 1,654 | 0.0% | 0.00% | – |
| Q2 2022 | $4,000 | -69.2% | 1,654 | 0.0% | 0.00% | – |
| Q3 2021 | $13,000 | -74.5% | 1,654 | -75.1% | 0.00% | – |
| Q1 2020 | $51,000 | +2450.0% | 6,648 | +1595.9% | 0.00% | – |
| Q3 2019 | $2,000 | +100.0% | 392 | +326.1% | 0.00% | – |
| Q2 2019 | $1,000 | 0.0% | 92 | 0.0% | 0.00% | – |
| Q1 2019 | $1,000 | -97.4% | 92 | -98.0% | 0.00% | – |
| Q4 2018 | $38,000 | -40.6% | 4,664 | -6.6% | 0.00% | -100.0% |
| Q3 2018 | $64,000 | -45.3% | 4,991 | -51.2% | 0.00% | 0.0% |
| Q2 2018 | $117,000 | +5750.0% | 10,221 | +3924.0% | 0.00% | – |
| Q3 2017 | $2,000 | -89.5% | 254 | -94.3% | 0.00% | – |
| Q2 2017 | $19,000 | -34.5% | 4,454 | -29.9% | 0.00% | – |
| Q1 2017 | $29,000 | +314.3% | 6,354 | +369.3% | 0.00% | – |
| Q4 2016 | $7,000 | -12.5% | 1,354 | +8.0% | 0.00% | – |
| Q3 2016 | $8,000 | – | 1,254 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sargent Investment Group, LLC | 249,430 | $2,015,000 | 1.24% |
| Manatuck Hill Partners, LLC | 194,100 | $1,568,000 | 0.81% |
| Skylands Capital, LLC | 495,850 | $4,006,000 | 0.66% |
| EAM Global Investors LLC | 78,027 | $630,000 | 0.34% |
| EAM Investors, LLC | 107,531 | $869,000 | 0.24% |
| Granahan Investment Management | 278,170 | $2,248,000 | 0.16% |
| Wealthcare Advisory Partners LLC | 62,079 | $502,000 | 0.10% |
| Avenir Corp | 76,390 | $617,000 | 0.08% |
| Crow Point Partners, LLC | 48,576 | $380,000 | 0.07% |
| Kalos Management, Inc. | 14,700 | $120,000 | 0.06% |